Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

BJ Monk, T Toita, X Wu, JCV Limón… - The lancet …, 2023 - thelancet.com
Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30–40% of treated patients have …
被引用次数：24 相关文章

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

BJ Monk, T Toita, X Wu, JCV Limón, R Tarnawski… - The Lancet …, 2023 - Elsevier
Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30–40% of treated patients have …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

B Monk, T Toita, X Wu, JV Limón… - The lancet …, 2023 - researchworks.creighton.edu
Abstract Adenocarcinoma Adenosquamous Adverse events Anemia Blood cells
Brachytherapy Cancer therapies Carboplatin Cervical cancer Chemoradiotherapy …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

BJ MONK, T TOITA, X WU, JCV LIMON… - Lancet …, 2023 - observatorio.fm.usp.br
Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30-40% of treated patients have …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.

BJ Monk, T Toita, X Wu, VL JC, R Tarnawski… - The Lancet …, 2023 - europepmc.org
Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30-40% of treated patients have …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

BJ Monk, T Toita, X Wu, JCV Limón… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30-40% of treated patients have …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

B Monk, T Toita, X Wu, JV Limón… - The lancet …, 2023 - researchworks.creighton.edu
Abstract Adenocarcinoma Adenosquamous Adverse events Anemia Blood cells
Brachytherapy Cancer therapies Carboplatin Cervical cancer Chemoradiotherapy …